Skip to main content

Select Drug Profiles

Integrating ACOs

Matthew C. Palmgren, PharmD

Issues in Affordable Cancer Care

Jennifer Malin, MD, PhD

Issues in Medical Adherence

John E. Hennessy, CMPE

Practice Management

Impact of Glycemic Control on Healthcare Resource Utilization and Costs of Type 2 Diabetes: Current and Future Pharmacologic Approaches to Improving Outcomes

Mary Ann Banerji, MD, FACP, Jeffrey D. Dunn, PharmD, MBA, Jeffrey A. Bourret, PharmD

Stakeholder Perspective

Innovation in Patient Engagement and Management Is Critically Needed to Change Current Trends in Type 2 Diabetes

Practice Management

Communication Strategies Must Be Tailored to a Medication’s Targeted Population: Lessons from the Case of BiDil

Chamika Hawkins-Taylor, MHA, PhD, Angeline M. Carlson, PhD

Stakeholder Perspective

Much More than Biomarkers: Sociodemographic Variables in Personalized Medicine

by Michael F. Murphy, MD, PhD

Practice Management

Yet Another Blow to the Medicaid Expansion

Igor Gorlach, JD, MPH, Ross D. Margulies, JD, MPH

Original Research

New Drug Therapies for the Treatment of Overweight and Obese Patients

Babak Mahgerefteh, DO, Michael Vigue, DO, Zachary Freestone, DO, Scott Silver, DO, Quang T. Nguyen, DO, FACE, FTOS

Stakeholder Perspective

The Modern Epidemic of Obesity

by James V. Felicetta, MD

Cardiometabolic Risk Factors: Novel Approaches Can Improve Patient Outcomes

Dalia Buffery, MA, ABD

Practice Management

Assessing Medicare Beneficiary Eligibility for Medication Therapy Management Programs Using PINNACLE, a National Cardiovascular Data Registry

Sarah A. Spinler, PharmD, Mark J. Cziraky, PharmD, Fengming Tang, MS, Gladys G. Dueñas, PharmD, Tyan Thomas, PharmD, Jennifer A. Reinhold, PharmD, Vincent J. Willey, PharmD

Stakeholder Perspective

Hanging Together for Patient-Centered Medical Care

by Albert Tzeel, MD, MHSA, CPE, FAAPL

Nesina, Kazano, and Oseni: Three Alogliptin-Based Agents Approved for the Treatment of Type 2 Diabetes

Page 171 of 244
Results 1701 - 1710 of 2438